+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Months +
All Genders
ID06923592

Cluster-Randomized Trial of Serological Testing and Targeted Treatment for Plasmodium Vivax Malaria in Ethiopia and Madagascar

Led by London School of Hygiene and Tropical Medicine · Updated on 2026-09-18

19200

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Plasmodium vivax malaria remains a challenge to elimination efforts due to its ability to form dormant liver stages called hypnozoites, which reactivate weeks to months after the initial infection causing relapses and continued transmission. These relapses contribute significantly to illness in affected individuals. Direct detection of hypnozoites is currently not possible, so researchers are evaluating an indirect approach using antibodies to specific P. vivax blood-stage antigens to identify recent infections within approximately the last 9 months. This trial compares two approaches in 48 clusters across Madagascar and Ethiopia. One group PvSeroTAT intervention will receive two rounds of serological testing at baseline and month 6 to detect recent P. vivax infections. Participants with positive antibody results and normal enzyme activity will be treated with primaquine for 7 or 14 days depending on location, alongside a three-day course of chloroquine or artesunate-amodiaquine. The control group will undergo similar testing but will not receive targeted treatment. Treatment adherence and side effects will be monitored during the first week after treatment. Participants are followed for 18 months with passive malaria case monitoring through health posts. Cross-sectional surveys at months 12 and 18 will measure P. vivax and P. falciparum prevalence using PCR testing. Outcomes include the proportion of individuals with detectable P. vivax infections after treatment rounds and the incidence of clinical malaria, as well as safety assessments like hemoglobin levels and adverse events. This study aims to assess the feasibility, acceptability, and effect of the PvSeroTAT strategy in reducing malaria relapses and transmission.

CONDITIONS

Brief Title

Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar

Research Team

R

Rob W van der Pluijm

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here